Login to Your Account



Pharma: Other News To Note


Wednesday, September 4, 2013
• Boehringer Ingelheim GmbH, of Ingelheim, Germany, entered a research service agreement with diagnostics firm Diaxonhit, of Paris, for the discovery and characterization of splice variants that have the potential to be therapeutic targets for oncology. With the agreement, Boehringer secures an option to acquire the rights to research, develop and commercialize any targets identified using Diaxonhit’s Splicearray discovery platform.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription